GIST as the Quintessential Solid Tumor Model for Targeted Therapy
Charles Blanke, MD, Professor of Medicine, Knight Cancer Institute/OHSU Chair, SWOG
Upon completion of this session, participants will be able to: Describe the concepts of targeted therapy and personalized medicine as applied to Oncology. To Illustrate understanding of background epidemiology and standard therapies for patients with GIST. To list the latest treatments and drugs/modalities in development of GISTs.
The University Of Oklahoma College Of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The University Of Oklahoma College Of Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University Of Oklahoma College Of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planned disclosures and resolved all identified conflicts of interest, if applicable.
Commercial Support: This activity has no commercial support.”
Course Director Planning Committee Member – Dr. Shubham Pant has no financial relationships or affiliations to disclose.
Course Contact – Cynthia Mitchell has no financial relationships or affiliations to disclose.
Speakers – Dr. Charles Blanke has no financial relationships or affiliations to disclose.
Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.
Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for an claims, injury and/or damage to person or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.
The University of Oklahoma is an Equal Opportunity Institution.
For accommodations on the basis of disability, call 405-271-4022.
For more information contact:
Department of Medicine/Hematology-Oncology